NeoGenomics guides 2025 revenue $735-745M, adj. EBITDA $55-58M; issues retention bonuses

NEOGENOMICS INC

2025 revenue guidance $735-745M (midpoint $740M) vs FY24 $661M, ~12% YoY growth.
2025 adjusted EBITDA guidance $55-58M vs FY24 $38.5M, up 43-51%.
Long-range plan: 12-13% annual revenue growth; NGS growth ~25% per year.
Retention bonuses: CFO Sherman ($400K cash + $750K RSUs), Presidents Harris and Stone each similar with vesting thru 2026.
Expects to retire 2025 convertible notes due May 1 with cash on hand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.